Hanna Bernstine1,2, Dafna Yahav3,1, Ili Margalit4,5, Anat Yahav6, Yaara Ben Ari1, Haim Ben-Zvi7, Avivit Shoham8, Elad Goldberg1,9, Michal Weiler-Sagie10,11, Noam Tau1,12, Khitam Muhsen13, Jihad Bishara3,1, Mical Paul11,14. 1. Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv-Yafo, Israel. 2. Nuclear Medicine Institute, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel. 3. Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, 39 Jabotinsky Road, Petah Tikva, Israel. 4. Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, 39 Jabotinsky Road, Petah Tikva, Israel. ilimargalit@gmail.com. 5. Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv-Yafo, Israel. ilimargalit@gmail.com. 6. Radiology Institute, Rambam Health Care Campus, Haifa, Israel. 7. Microbiology Laboratory, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel. 8. Department of Diagnostic Imaging, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel. 9. Department of Internal Medicine F, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel. 10. Nuclear Medicine Department, Rambam Health Care Campus, Haifa, Israel. 11. Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel. 12. Department of Diagnostic Imaging, Sheba Medical Center, Ramat Gan, Israel. 13. Department of Epidemiology and Preventive Medicine, Sackler Faculty of Medicine, School of Public Health, Tel Aviv University, Ramat Aviv, Tel Aviv-Yafo, Israel. 14. Infectious Diseases Institute, Rambam Health Care Campus, Haifa, Israel.
Abstract
INTRODUCTION: 18-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is a well-established tool for managing metastatic infections. Nocardiosis, a primarily pulmonary infection, disseminates at high rates. Routine imaging includes chest CT and brain imaging. We examined the use of FDG-PET/CT in nocardiosis and assessed its contribution to diagnosis and management. METHODS: A retrospective study in two tertiary medical centers during 2011-2020. Individuals with nocardiosis for whom FDG-PET/CT was implemented for any reason were included and their medical records were reviewed. A board-certified nuclear medicine physician independently reviewed all scans. Additionally, a systematic review was conducted according to the PRISMA guidelines, to extract data from publications reporting FDG-PET/CT use for the management of nocardiosis. RESULTS: FDG-PET/CT contributed to the management of all seven patients who met inclusion criteria. It assisted in ruling out an underlying malignancy (29%, 2/7); establishing a wide infection extent (57%, 4/7); and affecting decisions regarding treatment (57%, 4/7), including drug regimen, oral step-down, and duration of therapy. We identified 20 published case reports on this topic. In 80% (16/20), FDG-PET/CT contributed to the management of nocardiosis similar to our study. In addition, in most of the literature cases, FDG-PET/CT guided the diagnostic biopsy. CONCLUSION: FDG-PET/CT is valuable in the diagnosis and management of individuals with nocardiosis. The contribution of incorporating FDG-PET/CT to the management of individuals with nocardiosis and its role in monitoring treatment response and shortening treatment duration should be evaluated in prospective studies.
INTRODUCTION:18-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is a well-established tool for managing metastatic infections. Nocardiosis, a primarily pulmonary infection, disseminates at high rates. Routine imaging includes chest CT and brain imaging. We examined the use of FDG-PET/CT in nocardiosis and assessed its contribution to diagnosis and management. METHODS: A retrospective study in two tertiary medical centers during 2011-2020. Individuals with nocardiosis for whom FDG-PET/CT was implemented for any reason were included and their medical records were reviewed. A board-certified nuclear medicine physician independently reviewed all scans. Additionally, a systematic review was conducted according to the PRISMA guidelines, to extract data from publications reporting FDG-PET/CT use for the management of nocardiosis. RESULTS:FDG-PET/CT contributed to the management of all seven patients who met inclusion criteria. It assisted in ruling out an underlying malignancy (29%, 2/7); establishing a wide infection extent (57%, 4/7); and affecting decisions regarding treatment (57%, 4/7), including drug regimen, oral step-down, and duration of therapy. We identified 20 published case reports on this topic. In 80% (16/20), FDG-PET/CT contributed to the management of nocardiosis similar to our study. In addition, in most of the literature cases, FDG-PET/CT guided the diagnostic biopsy. CONCLUSION:FDG-PET/CT is valuable in the diagnosis and management of individuals with nocardiosis. The contribution of incorporating FDG-PET/CT to the management of individuals with nocardiosis and its role in monitoring treatment response and shortening treatment duration should be evaluated in prospective studies.
Authors: K Orvin; E Goldberg; H Bernstine; D Groshar; A Sagie; R Kornowski; J Bishara Journal: Clin Microbiol Infect Date: 2014-10-29 Impact factor: 8.067
Authors: Paola Anna Erba; Patrizio Lancellotti; Isidre Vilacosta; Oliver Gaemperli; Francois Rouzet; Marcus Hacker; Alberto Signore; Riemer H J A Slart; Gilbert Habib Journal: Eur J Nucl Med Mol Imaging Date: 2018-05-24 Impact factor: 9.236
Authors: Emanuele Palomba; Arianna Liparoti; Anna Tonizzo; Valeria Castelli; Laura Alagna; Giorgio Bozzi; Riccardo Ungaro; Antonio Muscatello; Andrea Gori; Alessandra Bandera Journal: Microorganisms Date: 2022-05-29